Biovaxys Technology Corp (BVAXF)

$0.09 0.00 (-0.11%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 10,100
Avg Vol 26,312
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 59%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell...

Industry: Biotechnology
Sector: Healthcare
Phone: 740-358-0555
Address:
146 Thirtieth Street, Suite 100, Etobicoke, Canada
StockEnthusiast1
StockEnthusiast1 Aug. 20 at 10:04 PM
$BVAXF no volume for 2 days? Any thoughts as to why?
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 20 at 4:28 PM
$BVAXF $BIOV.CSE Moderna/Merck cancer vaccine breakthrough validates combination neoantigen strategy. BIOV already executing this exact approach. Merck partnership, DPX proven in combination therapy, melanoma studies with Sona. When pharma validates the category, BIOV gets credibility for execution already proven.
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 19 at 5:06 PM
$BVAXF $BIOV.CSE Aug 19 DoD notification day for BIOV/Sona acral melanoma proposal. Invitation to full application = external validation of DPX platform independent of halt. Announcement timing is their choice. Results come today
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 18 at 4:06 PM
$BVAXF $BIOV.CSE Three realistic paths forward. Filing + raise, partnership/licensing, or acquisition. DPX delivery system IP is valuable regardless of which path. Aug 19 DoD notification tomorrow could accelerate the timeline.
1 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 17 at 5:12 PM
$BVAXF $BIOV.CSE DPX delivery system earning acquisition-level credibility from clinical professionals. External validation stacking, platform proof compounding. When mid-cap or big pharma sees what DPX can do, buyout becomes rational. Aug 19 DoD notification two days away.
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 14 at 3:32 PM
$BVAXF $BIOV.CSE 100% survival on burkholderia challenge. UK government and DTRA team picking DPX. Platform earning validation from credible sources. https://x.com/biovaxys/status/2087603946890399953
0 · Reply
MoneyMacG
MoneyMacG Aug. 14 at 12:14 AM
$BVAXF yeah this one might have something
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 13 at 4:43 PM
$BVAXF $BIOV.CSE CSE simplifying Form 7 requirements helps issuers, but BIOV's real blocker is filing completion lifting the halt. Aug 19 DoD notification could shift momentum while compliance catches up. Platform keeps earning credibility.
0 · Reply
wheresdannynow
wheresdannynow Aug. 12 at 6:56 PM
$BVAXF Quality people, quality data, and the platform keeps getting noticed despite the trading pause.
0 · Reply
wheresdannynow
wheresdannynow Aug. 12 at 6:56 PM
$BVAXF This is exactly the kind of independent signal that matters. BioVaxys’ PI on the PESCO ovarian study just took home the 2026 IGCS Lifetime Achievement Award.
0 · Reply
Latest News on BVAXF
No data available.
StockEnthusiast1
StockEnthusiast1 Aug. 20 at 10:04 PM
$BVAXF no volume for 2 days? Any thoughts as to why?
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 20 at 4:28 PM
$BVAXF $BIOV.CSE Moderna/Merck cancer vaccine breakthrough validates combination neoantigen strategy. BIOV already executing this exact approach. Merck partnership, DPX proven in combination therapy, melanoma studies with Sona. When pharma validates the category, BIOV gets credibility for execution already proven.
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 19 at 5:06 PM
$BVAXF $BIOV.CSE Aug 19 DoD notification day for BIOV/Sona acral melanoma proposal. Invitation to full application = external validation of DPX platform independent of halt. Announcement timing is their choice. Results come today
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 18 at 4:06 PM
$BVAXF $BIOV.CSE Three realistic paths forward. Filing + raise, partnership/licensing, or acquisition. DPX delivery system IP is valuable regardless of which path. Aug 19 DoD notification tomorrow could accelerate the timeline.
1 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 17 at 5:12 PM
$BVAXF $BIOV.CSE DPX delivery system earning acquisition-level credibility from clinical professionals. External validation stacking, platform proof compounding. When mid-cap or big pharma sees what DPX can do, buyout becomes rational. Aug 19 DoD notification two days away.
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 14 at 3:32 PM
$BVAXF $BIOV.CSE 100% survival on burkholderia challenge. UK government and DTRA team picking DPX. Platform earning validation from credible sources. https://x.com/biovaxys/status/2087603946890399953
0 · Reply
MoneyMacG
MoneyMacG Aug. 14 at 12:14 AM
$BVAXF yeah this one might have something
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 13 at 4:43 PM
$BVAXF $BIOV.CSE CSE simplifying Form 7 requirements helps issuers, but BIOV's real blocker is filing completion lifting the halt. Aug 19 DoD notification could shift momentum while compliance catches up. Platform keeps earning credibility.
0 · Reply
wheresdannynow
wheresdannynow Aug. 12 at 6:56 PM
$BVAXF Quality people, quality data, and the platform keeps getting noticed despite the trading pause.
0 · Reply
wheresdannynow
wheresdannynow Aug. 12 at 6:56 PM
$BVAXF This is exactly the kind of independent signal that matters. BioVaxys’ PI on the PESCO ovarian study just took home the 2026 IGCS Lifetime Achievement Award.
0 · Reply
wheresdannynow
wheresdannynow Aug. 12 at 6:55 PM
$BVAXF Dr. Oza getting the IGCS Lifetime Achievement Award for work that includes the PESCO trial with MVP-S
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 12 at 4:51 PM
$BVAXF $BIOV.CSE Dr. Oza receiving IGCS Lifetime Achievement Award validates the clinical leadership running DPX trials. PESCO study with MVP-S advancing. Platform earning credibility from the people who matter. Aug 19 validation checkpoint coming. https://x.com/biovaxys/status/2087312269768073376
0 · Reply
FLArnot
FLArnot Aug. 12 at 1:14 AM
$BVAXF Down over 55% over one year.
0 · Reply
FLArnot
FLArnot Aug. 12 at 1:13 AM
$BVAXF No update from management on CTO.
0 · Reply
FLArnot
FLArnot Aug. 12 at 1:12 AM
$BVAXF Cease Trade Order for over a full quarter of year.
0 · Reply
Ventureville
Ventureville Aug. 11 at 6:17 PM
$BVAXF Saw the CSE notice ending mandatory Form 7s; one less administrative item for issuers.
0 · Reply
Ventureville
Ventureville Aug. 11 at 6:17 PM
$BVAXF CSE dropping Form 7s is interesting, but yeah the filing delay and halt have dragged way too long. Still waiting on that actual status update.
0 · Reply
Ventureville
Ventureville Aug. 11 at 6:16 PM
$BVAXF CSE simplifying rules by ditching monthly Form 7s is a small positive for the exchange. Now if BioVaxys can just clear the overdue filings and lift the halt, the underlying DPX tech and earlier positive readouts in ovarian/bladder get a chance to drive the conversation again.
0 · Reply
ProfitWhisperer
ProfitWhisperer Aug. 11 at 5:35 PM
$BVAXF $BIOV.CSE Aug 19 matters because it's a DoD panel evaluating BIOV/Sona acral melanoma work, separate from BIOV's own narrative. External validation happening while the halt sits. Platform gets credibility from people with zero financial exposure to the stock.
0 · Reply
Davidendz
Davidendz Aug. 10 at 5:32 PM
$BVAXF Hoping the next update finally moves things forward so the platform can be evaluated on its merits again.
0 · Reply
Davidendz
Davidendz Aug. 10 at 5:32 PM
$BVAXF Still no official word on the delayed filings or when trading resumes, that’s the reality right now.
0 · Reply
Davidendz
Davidendz Aug. 10 at 5:31 PM
$BVAXF Anyone catch any new news? Still waiting on that update so we can get trading back and focus on the actual pipeline.
0 · Reply